Clinical Trial Detail

NCT ID NCT02393625
Title Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals

lung non-small cell carcinoma


Ceritinib + Nivolumab

Age Groups: adult

Additional content available in CKB BOOST